rhu-pGSN for COVID-19: real-time analysis

Download Image

Post

c19early.org

rhu-pGSN for COVID-19

1 study with 61 patients

Serious outcome risk

rhu-pGSN

Control

No significant improvements are seen in meta-analysis to date.

COVID-19 rhu-pGSN studies · October 2026

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)−3%

Mortality (1)−3%

RCTs (1)−3%

Late (1)−3%

00.511.5+

← rhu-pGSN
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}

Recombinant human plasma gelsolin (rhu-pGSN) is a biologic therapy that functions as a host-directed anti-inflammatory and immunomodulatory agent.


Jul 25 2022	DiNubile et al., Open Forum Infectious Diseases, doi:10.1093/ofid/ofac357	Adjunctive Recombinant Human Plasma Gelsolin for Severe Coronavirus Disease 2019 Pneumonia
Jul 25 2022	3% higher mortality (p=1), 48% lower ventilation (p=0.47), and 29% higher progression (p=0.73). RCT 61 hospitalized patients with COVID-19 pneumonia showing no significant difference in survival without major organ support with recombinant human plasma gelsolin (rhu-pGSN). This double-blind, placebo-controlled trial evaluated rhu-pG..